ABEO
Abeona Therapeutics Inc.
Price Chart
Latest Quote
$5.17
Current Price| Previous Close | $5.09 |
| Open | $5.10 |
| Day High | $5.23 |
| Day Low | $4.99 |
| Volume | 746,918 |
Stock Information
| Shares Outstanding | 54.19M |
| Total Debt | $24.11M |
| Cash Equivalents | $207.12M |
| Revenue | $400K |
| Net Income | $82.35M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $280.17M |
| P/E Ratio | 4.27 |
| EPS (TTM) | $1.21 |
| Exchange | NCM |
đ Custom Metrics & Score
Score: 7/42| Debt to Equity | 0.52 |
| Current Ratio | 6.08 |
| Quick Ratio | 5.99 |
| Avg Revenue Growth | -25.00% |
| Return on Equity | -144.75% |
| Avg FCF Growth | -4.07% |
| FCF Yield | -20.87% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $5.17 | 746,918 |
| 2026-01-30 | $5.09 | 672,900 |
| 2026-01-29 | $5.08 | 1,629,200 |
| 2026-01-28 | $4.83 | 2,117,000 |
| 2026-01-27 | $5.11 | 1,046,900 |
| 2026-01-26 | $5.19 | 1,014,100 |
| 2026-01-23 | $5.16 | 1,398,200 |
| 2026-01-22 | $5.36 | 1,363,800 |
| 2026-01-21 | $5.31 | 1,194,800 |
| 2026-01-20 | $5.31 | 1,393,600 |
| 2026-01-16 | $5.25 | 2,155,400 |
| 2026-01-15 | $5.45 | 1,620,600 |
| 2026-01-14 | $5.19 | 721,400 |
| 2026-01-13 | $5.09 | 761,700 |
| 2026-01-12 | $5.10 | 1,217,800 |
| 2026-01-09 | $5.19 | 1,363,700 |
| 2026-01-08 | $5.09 | 1,659,900 |
| 2026-01-07 | $5.22 | 1,113,200 |
| 2026-01-06 | $5.16 | 1,172,400 |
| 2026-01-05 | $5.22 | 1,101,700 |
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
đ° Latest News
Insider-Favored Growth Companies To Watch February 2026
Simply Wall St. âĸ 2026-02-02T17:35:51Z
3 Insider-Owned Growth Stocks For Your Watchlist
Simply Wall St. âĸ 2026-01-01T17:35:48Z
November 2025's High Growth Companies With Insider Influence
Simply Wall St. âĸ 2025-11-13T17:36:00Z
Abeona Therapeutics (ABEO) Is Up 17.9% After Reporting Narrowed Losses and ZEVASKYN J-code Approval
Simply Wall St. âĸ 2025-11-13T10:22:20Z
Abeona Therapeutics Inc (ABEO) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...
GuruFocus.com âĸ 2025-11-12T21:01:55Z
Here's Why Abeona Therapeutics Popped Higher Today
Motley Fool âĸ 2025-11-12T16:37:50Z
Abeona Therapeutics: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-12T12:40:49ZA Look at Abeona Therapeutics (ABEO) Valuation After CMS J-Code Approval and Ahead of Q3 Earnings
Simply Wall St. âĸ 2025-11-12T07:08:44Z
3 Top Growth Stocks Insiders Are Eager To Hold
Simply Wall St. âĸ 2025-10-10T17:35:40Z
Should You Invest in Abeona Therapeutics (ABEO)?
Insider Monkey âĸ 2025-09-08T12:28:52Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $0 | $1,605,000 | $450,000 | $0 |
| Cost Of Revenue | $0 | $1,605,000 | $450,000 | $0 |
| Total Revenue | $0 | $3,500,000 | $1,414,000 | $3,000,000 |
| Operating Revenue | $0 | $3,500,000 | $1,414,000 | $3,000,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $4,208,000 | $418,000 | $736,000 | $3,656,000 |
| Total Expenses | $64,211,000 | $51,700,000 | $46,671,000 | $60,370,000 |
| Other Income Expense | $439,000 | $-7,687,000 | $5,866,000 | $-23,950,000 |
| Other Non Operating Income Expenses | $1,194,000 | $2,943,000 | $141,000 | $15,000 |
| Net Non Operating Interest Income Expense | $38,000 | $1,699,000 | $-305,000 | $-3,616,000 |
| Interest Expense Non Operating | $4,208,000 | $418,000 | $736,000 | $3,656,000 |
| Operating Expense | $64,211,000 | $50,095,000 | $46,221,000 | $60,370,000 |
| General And Administrative Expense | $29,851,000 | $19,004,000 | $17,256,000 | $21,644,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-63,734,000 | $-54,188,000 | $-39,696,000 | $-84,936,000 |
| Net Interest Income | $38,000 | $1,699,000 | $-305,000 | $-3,616,000 |
| Interest Income | $4,246,000 | $2,117,000 | $431,000 | $40,000 |
| Normalized Income | $-62,979,000 | $-43,558,000 | $-45,421,000 | $-60,971,000 |
| Net Income From Continuing And Discontinued Operation | $-63,734,000 | $-54,188,000 | $-39,696,000 | $-84,936,000 |
| Total Operating Income As Reported | $-64,211,000 | $-47,135,000 | $-50,915,000 | $-89,836,000 |
| Net Income Common Stockholders | $-63,734,000 | $-54,188,000 | $-43,478,000 | $-84,936,000 |
| Net Income | $-63,734,000 | $-54,188,000 | $-39,696,000 | $-84,936,000 |
| Net Income Including Noncontrolling Interests | $-63,734,000 | $-54,188,000 | $-39,696,000 | $-84,936,000 |
| Net Income Continuous Operations | $-63,734,000 | $-54,188,000 | $-39,696,000 | $-84,936,000 |
| Pretax Income | $-63,734,000 | $-54,188,000 | $-39,696,000 | $-84,936,000 |
| Special Income Charges | $0 | $1,065,000 | $-5,658,000 | $-23,965,000 |
| Interest Income Non Operating | $4,246,000 | $2,117,000 | $431,000 | $40,000 |
| Operating Income | $-64,211,000 | $-48,200,000 | $-45,257,000 | $-57,370,000 |
| Gross Profit | $0 | $1,895,000 | $964,000 | $3,000,000 |
| Depreciation Amortization Depletion Income Statement | - | - | - | $3,250,000 |
| Depreciation And Amortization In Income Statement | - | - | - | $3,250,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-1.55 | $-2.53 | $-5.53 | $-21.50 |
| Basic EPS | $-1.55 | $-2.53 | $-5.53 | $-21.50 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-55,864,000 | $-39,942,000 | $-40,108,000 | $-52,851,000 |
| Total Unusual Items | $-755,000 | $-10,630,000 | $5,725,000 | $-23,965,000 |
| Total Unusual Items Excluding Goodwill | $-755,000 | $-10,630,000 | $5,725,000 | $-23,965,000 |
| Reconciled Depreciation | $2,907,000 | $3,198,000 | $4,577,000 | $4,464,000 |
| EBITDA (Bullshit earnings) | $-56,619,000 | $-50,572,000 | $-34,383,000 | $-76,816,000 |
| EBIT | $-59,526,000 | $-53,770,000 | $-38,960,000 | $-81,280,000 |
| Diluted Average Shares | $41,048,206 | $21,380,476 | $7,861,515 | $3,937,676 |
| Basic Average Shares | $41,048,206 | $21,380,476 | $7,861,515 | $3,937,676 |
| Diluted NI Availto Com Stockholders | $-63,734,000 | $-54,188,000 | $-43,478,000 | $-84,936,000 |
| Gain On Sale Of Ppe | $0 | $1,065,000 | $-2,511,000 | - |
| Gain On Sale Of Security | $-755,000 | $-11,695,000 | $11,383,000 | - |
| Research And Development | $34,360,000 | $31,091,000 | $28,965,000 | $38,726,000 |
| Selling General And Administration | $29,851,000 | $19,004,000 | $17,256,000 | $21,644,000 |
| Other Gand A | $29,851,000 | $19,004,000 | $17,256,000 | $21,644,000 |
| Impairment Of Capital Assets | - | $0 | $3,147,000 | $32,466,000 |
| Preferred Stock Dividends | - | - | $3,782,000 | - |
| Other Special Charges | - | - | - | $-8,501,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $44,031,000 | $14,826,000 | $26,761,000 | $40,984,000 |
| Total Assets | $108,931,000 | $64,002,000 | $64,214,000 | $79,586,000 |
| Total Non Current Assets | $8,078,000 | $8,265,000 | $11,115,000 | $23,294,000 |
| Other Non Current Assets | $96,000 | $277,000 | $43,000 | $168,000 |
| Current Assets | $100,853,000 | $55,737,000 | $53,099,000 | $56,292,000 |
| Other Current Assets | $1,143,000 | $729,000 | $424,000 | $2,377,000 |
| Restricted Cash | $338,000 | $338,000 | $338,000 | $5,891,000 |
| Receivables | $1,652,000 | $2,444,000 | $188,000 | $3,000,000 |
| Other Receivables | $1,652,000 | $2,444,000 | $188,000 | - |
| Cash Cash Equivalents And Short Term Investments | $97,720,000 | $52,226,000 | $52,149,000 | $45,024,000 |
| Cash And Cash Equivalents | $23,357,000 | $14,473,000 | $14,217,000 | $32,938,000 |
| Goodwill And Other Intangible Assets | - | - | $0 | $1,384,000 |
| Accounts Receivable | - | - | $0 | $3,000,000 |
| Other Intangible Assets | - | - | - | $1,384,000 |
| Prepaid Assets | - | - | - | $7,377,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $23,048,000 | $5,400,000 | $7,627,000 | $9,378,000 |
| Long Term Debt And Capital Lease Obligation | $16,299,000 | $4,402,000 | $5,854,000 | $7,560,000 |
| Long Term Debt | $13,037,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $6,749,000 | $998,000 | $1,773,000 | $1,818,000 |
| Current Debt | $5,926,000 | - | - | - |
| Other Current Borrowings | $5,926,000 | - | - | - |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $64,900,000 | $49,176,000 | $37,453,000 | $37,218,000 |
| Total Non Current Liabilities Net Minority Interest | $48,313,000 | $35,754,000 | $29,674,000 | $20,595,000 |
| Derivative Product Liabilities | $32,014,000 | $31,352,000 | $19,657,000 | $9,007,000 |
| Current Liabilities | $16,587,000 | $13,422,000 | $7,779,000 | $16,623,000 |
| Other Current Liabilities | $64,000 | $1,000 | $204,000 | $296,000 |
| Payables And Accrued Expenses | $5,382,000 | $8,735,000 | $3,209,000 | $12,715,000 |
| Payables | $3,441,000 | $6,438,000 | $1,811,000 | $8,924,000 |
| Accounts Payable | $3,441,000 | $1,858,000 | $1,811,000 | $4,325,000 |
| Tradeand Other Payables Non Current | - | $0 | $4,163,000 | $3,828,000 |
| Other Payable | - | $4,580,000 | - | $4,599,000 |
| Other Non Current Liabilities | - | - | - | $200,000 |
| Current Deferred Liabilities | - | - | - | $296,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $44,031,000 | $14,826,000 | $26,761,000 | $42,368,000 |
| Total Equity Gross Minority Interest | $44,031,000 | $14,826,000 | $26,761,000 | $42,368,000 |
| Stockholders Equity | $44,031,000 | $14,826,000 | $26,761,000 | $42,368,000 |
| Gains Losses Not Affecting Retained Earnings | $8,000 | $-66,000 | $-129,000 | $-27,000 |
| Other Equity Adjustments | $8,000 | $-66,000 | $-129,000 | $-27,000 |
| Retained Earnings | $-813,258,000 | $-749,524,000 | $-695,336,000 | $-655,640,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Preferred Shares Number | $29,383,617 | $29,383,617 | $29,383,617 | $29,383,617 |
| Ordinary Shares Number | $45,644,091 | $26,523,878 | $17,719,720 | $5,888,216 |
| Share Issued | $45,644,091 | $26,523,878 | $17,719,720 | $5,888,216 |
| Tangible Book Value | $44,031,000 | $14,826,000 | $26,761,000 | $40,984,000 |
| Invested Capital | $62,994,000 | $14,826,000 | $26,761,000 | $42,368,000 |
| Working Capital | $84,266,000 | $42,315,000 | $45,320,000 | $39,669,000 |
| Capital Lease Obligations | $4,085,000 | $5,400,000 | $7,627,000 | $9,378,000 |
| Total Capitalization | $57,068,000 | $14,826,000 | $26,761,000 | $42,368,000 |
| Additional Paid In Capital | $856,824,000 | $764,151,000 | $722,049,000 | $696,563,000 |
| Capital Stock | $457,000 | $265,000 | $177,000 | $1,472,000 |
| Common Stock | $457,000 | $265,000 | $177,000 | $1,472,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $3,262,000 | $4,402,000 | $5,854,000 | $7,560,000 |
| Current Capital Lease Obligation | $823,000 | $998,000 | $1,773,000 | $1,818,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,392,000 | $3,688,000 | $2,593,000 | $1,794,000 |
| Current Accrued Expenses | $1,941,000 | $2,297,000 | $1,398,000 | $3,791,000 |
| Net PPE | $7,982,000 | $7,988,000 | $11,072,000 | $21,742,000 |
| Accumulated Depreciation | $-14,980,000 | $-12,991,000 | $-11,879,000 | $-10,460,000 |
| Gross PPE | $22,962,000 | $20,979,000 | $22,951,000 | $32,202,000 |
| Leases | $8,805,000 | $8,603,000 | $8,605,000 | $8,603,000 |
| Construction In Progress | $624,000 | $0 | $0 | $3,219,000 |
| Other Properties | $12,420,000 | $11,390,000 | $12,967,000 | $18,484,000 |
| Machinery Furniture Equipment | $1,113,000 | $986,000 | $1,379,000 | $1,896,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $74,363,000 | $37,753,000 | $37,932,000 | $12,086,000 |
| Current Deferred Revenue | - | - | - | $296,000 |
| Goodwill | - | - | - | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-58,461,000 | $-37,340,000 | $-43,613,000 | $-69,816,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-56,015,000 | $-37,009,000 | $-43,483,000 | $-65,665,000 |
| Cash Flow From Continuing Operating Activities | $-56,015,000 | $-37,009,000 | $-43,483,000 | $-65,665,000 |
| Operating Gains Losses | $753,000 | $10,677,000 | $-9,026,000 | $-1,758,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-2,446,000 | $-331,000 | $-130,000 | $-4,151,000 |
| Investing Cash Flow | $-39,240,000 | $208,000 | $-23,964,000 | $66,062,000 |
| Cash Flow From Continuing Investing Activities | $-39,240,000 | $208,000 | $-23,964,000 | $66,062,000 |
| Capital Expenditure Reported | $-2,446,000 | $-331,000 | $-130,000 | $-4,151,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $85,628,000 | $37,389,000 | $69,428,000 | $24,030,000 |
| Financing Cash Flow | $104,139,000 | $37,057,000 | $43,173,000 | $24,861,000 |
| Cash Flow From Continuing Financing Activities | $104,139,000 | $37,057,000 | $43,173,000 | $24,861,000 |
| Net Other Financing Charges | $-1,489,000 | $-332,000 | - | $-1,454,000 |
| Net Common Stock Issuance | $85,628,000 | $37,389,000 | $46,960,000 | $24,030,000 |
| Common Stock Issuance | $85,628,000 | $37,389,000 | $46,960,000 | $24,030,000 |
| Repurchase Of Capital Stock | - | $0 | $-26,250,000 | $0 |
| Net Preferred Stock Issuance | - | $0 | $-3,782,000 | $0 |
| Preferred Stock Issuance | - | $0 | $22,468,000 | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Debt | $20,000,000 | $0 | - | $0 |
| Interest Paid Supplemental Data | $2,670,000 | $0 | - | $0 |
| Income Tax Paid Supplemental Data | $7,000 | $14,000 | - | $0 |
| End Cash Position | $23,695,000 | $14,811,000 | $14,555,000 | $38,829,000 |
| Beginning Cash Position | $14,811,000 | $14,555,000 | $38,829,000 | $13,571,000 |
| Changes In Cash | $8,884,000 | $256,000 | $-24,274,000 | $25,258,000 |
| Net Issuance Payments Of Debt | $20,000,000 | $0 | - | $0 |
| Net Long Term Debt Issuance | $20,000,000 | $0 | - | $0 |
| Long Term Debt Issuance | $20,000,000 | $0 | - | $0 |
| Net Investment Purchase And Sale | $-36,812,000 | $335,000 | $-25,568,000 | $70,213,000 |
| Sale Of Investment | $120,198,000 | $51,971,000 | $52,644,000 | $90,376,000 |
| Purchase Of Investment | $-157,010,000 | $-51,636,000 | $-78,212,000 | $-20,163,000 |
| Net PPE Purchase And Sale | $18,000 | $204,000 | $1,734,000 | $0 |
| Sale Of PPE | $18,000 | $204,000 | $1,734,000 | $0 |
| Change In Working Capital | $-4,383,000 | $-1,788,000 | $-5,892,000 | $-18,263,000 |
| Change In Other Current Liabilities | $-1,299,000 | $-1,399,000 | $-1,674,000 | - |
| Change In Other Current Assets | $181,000 | $-234,000 | $125,000 | $-7,000 |
| Change In Payables And Accrued Expense | $-3,493,000 | $2,041,000 | $-9,108,000 | $-15,587,000 |
| Change In Payable | $-3,493,000 | $2,041,000 | $-9,108,000 | $-15,587,000 |
| Change In Account Payable | $-3,493,000 | $2,041,000 | $-9,108,000 | $-15,587,000 |
| Change In Prepaid Assets | $-564,000 | $-155,000 | $1,953,000 | $331,000 |
| Change In Receivables | $792,000 | $-2,041,000 | $2,812,000 | $-3,000,000 |
| Other Non Cash Items | $1,814,000 | $324,000 | $356,000 | $-6,554,000 |
| Stock Based Compensation | $6,628,000 | $4,768,000 | $3,051,000 | $8,916,000 |
| Depreciation Amortization Depletion | $2,907,000 | $3,198,000 | $4,577,000 | $4,464,000 |
| Depreciation And Amortization | $2,907,000 | $3,198,000 | $4,577,000 | $4,464,000 |
| Depreciation | $2,907,000 | $3,198,000 | $4,577,000 | $4,464,000 |
| Gain Loss On Investment Securities | $755,000 | $11,695,000 | $-11,383,000 | - |
| Gain Loss On Sale Of PPE | $-2,000 | $-1,018,000 | $2,357,000 | $0 |
| Net Income From Continuing Operations | $-63,734,000 | $-54,188,000 | $-39,696,000 | $-84,936,000 |
| Proceeds From Stock Option Exercised | - | $-182,000 | $-5,000 | $831,000 |
| Preferred Stock Payments | - | $0 | $-26,250,000 | $0 |
| Changes In Account Receivables | - | $0 | $3,000,000 | $-3,000,000 |
| Asset Impairment Charge | - | $0 | $3,147,000 | $32,466,000 |
| Change In Other Working Capital | - | - | $-292,000 | $-7,000 |